Shared Resource Core A. Imaging. Daniel Barboriak, M.D., Core Director The role of the Imaging Core is to evaluate therapeutic response for novel therapies in neuro-oncology and to evaluate treatment delivery. The Imaging Core has five Specific Aims/Goals. 1. To perform and implement response assessment based on a modification of RECIST 1.1 in patients with neoplastic meningitis being treated with [211]-At-labeled trastuzumab and panitumumab. The modification of RECIST 1.1 of Project 1 will allow the treatment response as evaluated by cerebrospinal fluid (CSF) cytology to be integrated with the imaging-based response. Successful implementation of this image response assessment will be ensured using a quality control regimen which includes training sessions, oversight and review by subspecialty board-certified neuroradiologists with at least 2 years of subspecialty experience, and auditing of cases by the Core Director. 2. To perform and implement RANO (response assessment in neuro-oncology) criteria for evaluation of response in patients undergoing immunotherapy for newly diagnosed glioblastoma multiforme (GSM, Project 2) and immunotoxin treatment for recurrent GBM (Project 3). The implementation considerations for this new image response assessment are identical to those above. 3. To assess dose distribution of EGFR and EGFRvlll-dual-specific Immunotoxin (Project 3), using combined gadolinium and [124]I -albumin infusion to evaluate convection-enhanced delivery (CED). As part of this project, imaging results will be used to improve the simulation of CED dose distribution. 4. To evaluate the distribution of [124] l-labeled trastuzumab by PET imaging of both animal and human subjects. These experiments will evaluate the potential utility of [124] l-labeled trastuzumab as a PET Imaging probe for monitoring response to therapy and possibly define dose-response relationships. 5. To oversee and provide technical support for the administration of radiopharmaceuticals. This includes fluoroscopically-guided access of the Rickham or Ommaya reservoirs (Project 1) and overseeing the radioactive component of the intratumoral infusions (Project 3).

Public Health Relevance

Core activities will test the feasibility and face validity of therapeutic evaluation using the RECIST 1.1 and RANO criteria, which have yet to be broadly implemented in clinical neuro-imaging trials and may or may not be valid for evaluation of novel radio-antibody, immunotoxin or immunotherapy treatments. The effectiveness of convection-enhanced dose delivery will be evaluated using gamma camera and PET scanning

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA154291-03
Application #
8724202
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$740,483
Indirect Cost
$232,966
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Bao, Xuhui; Chandramohan, Vidyalakshmi; Reynolds, Randall P et al. (2016) Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Invest New Drugs 34:149-58
Suryadevara, Carter M; Riccione, Katherine A; Sampson, John H (2016) Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. Clin Cancer Res 22:5164-5166
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Pruszyński, Marek; Łyczko, Monika; Bilewicz, Aleksander et al. (2015) Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. Nucl Med Biol 42:439-45
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2015) D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nucl Med Biol 42:19-27
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6
Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia et al. (2014) N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol 41:802-12
Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5

Showing the most recent 10 out of 19 publications